CORRADINI, PAOLO
CORRADINI, PAOLO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study
2026 L. Farina, A. Noto, A. Aiello, M. Motta, A. Ferrario, R. Moia, L. Scarfò, M. Deodato, M. Merli, S. Ljevar, G. Pruneri, C. Carniti, P. Corradini
Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study
2026 N. Polverelli, C. Zerbi, M.G. Benevento, M. Algeri, A. Algarotti, E. Angelucci, A.C. Balduzzi, M. Basiricò, S. Bassi, G. Battipaglia, E. Benedetti, A. Biffi, F. Bonifazi, C. Borghero, S. Bramanti, L. Brunello, P. Bresciani, A. Busca, R. Cairoli, P. Carluccio, F. Carobolante, A.M. Carella, I.M. Cavattoni, R. Cerretti, A. Chiappella, P. Chiusolo, M. Cimminiello, P. Corradini, A. Crescimanno, A. Cuoghi, N. Di Renzo, F. Fagioli, R. Fanin, M. Faraci, V. Federico, A. Geromin, L. Giaccone, A. Giacomazzi, A. Grassi, G. Grillo, A. Imovilli, C. Ingrosso, A.P. Iori, G. La Nasa, S. Leotta, M.T. Lupo Stanghellini, G. Mancini, J. Mariotti, A. Mele, M. Menconi, F. Merli, N. Mordini, M. Musso, C. Nozzoli, F. Pane, M. Parma, R. Pastano, D. Pastore, F. Patriarca, A. Picardi, S. Piemontese, A. Pierini, E. Piras, F. Porta, G. Porto, A. Prete, L. Prezioso, A. Proia, A. Raiola, R. Ricci, M. Roberto, C. Rosignoli, D. Russo, D. Salvatore, S. Santarone, G. Saporiti, F. Saraceni, C. Selleri, B. Serio, C. Skert, S. Sica, A. Spina, F.P. Tambaro, C. Tecchio, E. Terruzzi, M. Tumino, D. Vallisa, F. Zallio, M. Zecca, A. Taurino, A. Bianchessi, I. Defrancesco, G. Losi, E. Degrandi, M. Malagola, L. Castagna, M. Martino
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial
2026 H. Einsele, J. San-Miguel, B. Dhakal, C. Touzeau, X. Leleu, N.W. Van De Donk, S. Sidana, A. Oriol, Y.C. Cohen, S.J. Harrison, M. Mateos, J. Martínez-López, P. Corradini, L. Karlin, D. Chen, Q. Li, T. Yeh, K. Li, V. Plaks, A. Slaughter, C. Lonardi, N. Benachour, A. Ghosh, M. Vogel, J.M. Schecter, N. Lendvai, M. Koneru, N. Patel, E. Florendo, P.J. Ho, R. Popat
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma
2026 R.T. Maziarz, M.R. Bishop, C.S. Tam, P. Borchmann, N. Worel, J.P. Mcguirk, H. Holte, E.K. Waller, S. Jaglowski, C. Andreadis, S.R. Foley, J.R. Westin, I. Fleury, P.J. Ho, S. Mielke, T. Teshima, M. Janakiram, J. Hsu, K. Izutsu, M.J. Kersten, M. Ghosh, N. Wagner-Johnston, K. Kato, P. Corradini, W. Ma, X. Han, M. Nuortti, R. Awasthi, K.E. Mundt, M. Majdan, H.J. Maier, A. Jegerlehner, G. Salles, S.J. Schuster
Systemic inflammation and CAR-T specific toxicities as major drivers of non-relapse mortality: analysis from the Italian prospective observational CART-SIE Study
2026 A. Barone, F. Stella, S. Ljevar, B. Casadei, S. Bramanti, P. Chiusolo, A.D. Rocco, M.C. Tisi, I. Cutini, P. Angelillo, M. Martino, M. Musso, M. Farina, M. Pennisi, A.M. Barbui, R. Freilone, J. Olivieri, G. Grillo, P. Musto, F. Saraceni, M. Krampera, L. Brunello, A. Castellino, S. Ragaini, L. Arcaini, A. Chiappella, A. Guidetti, A. Dodero, R. Miceli, P. Zinzani, P. Corradini
Polatuzumab vedotin-containing regimens as bridge to CART: analysis from the CART-SIE study
2026 G. Gabrielli, B. Casadei, A. Chiappella, M.C. Tisi, E. Galli, I. Cutini, A. Di Rocco, L. Donzelli, M. Martino, G. Policastro, A. Crescimanno, G. Petruzzellis, F. Stella, C. Visco, M. Krampera, M. Farina, P. Angelillo, L. Brunello, B. Bruno, D. Mannina, M. Novo, G. Grillo, L. Argnani, F. Bonifazi, P. Corradini, P.L. Zinzani
An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myeloma
2026 P. Corradini, P. Musto, C. Galeone, P. Mariani, F. Resci, M. Cavo
Long-Term Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: An Italian Multicenter Collaborative Study
2025 C. Tarella, S. Sammassimo, S. Frassoni, A. Dominietto, R. Cerretti, M.C. Micò, R. Pastano, M. Pennisi, M.C.D. Chio, C. Ghiggi, G. De Angelis, A. Algarotti, P. Chiusolo, E. Derenzini, S. Sica, P. Corradini, V. Bagnardi, E. Angelucci, A. Rambaldi, W.G. Arcese, A. Dodero, A. Bacigalupo
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial
2025 M. Hutchings, A. Sureda, F. Bosch, T.S. Larsen, P. Corradini, A. Avigdor, M.J. Terol, A.R. Dominguez, A. Pinto, A. Skarbnik, R. Cordoba, J.M. Jørgensen, P.L. Zinzani, W. Leung, A. Bottos, D. Li, J. Relf, M. Tandon, G. Sellam, G. Gritti
Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus
2025 S. Luminari, A. Chiappella, A.D. Rocco, L. Arcaini, R. Freilone, M. Ladetto, M. Martino, P. Musto, L. Rigacci, C. Visco, P. Corradini, P.L. Zinzani
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials
2025 S. Viviani, C. Pavoni, S.F. Barrington, L. Guerra, H. Schöder, P. Johnson, A.A. Kirkwood, D.M. Stephens, J.W. Friedberg, S. Chauvie, M.V. Knopp, S. Luminari, D. Molin, P. Corradini, A. Gallamini, A. Rambaldi, C. Tarella
Treatment persistence and overall survival in myelofibrosis treated with ruxolitinib were not affected by the covid-19 pandemic, despite the reduced starting dose: Analysis of AIFA registries
2025 M. Breccia, S. Celant, F. Palandri, F. Passamonti, P.P. Olimpieri, V. Summa, A. Guarcello, G.A. Palumbo, F. Pane, P. Guglielmelli, P. Zinzani, P. Corradini, P. Russo
Prospective Validation of CAR-HEMATOTOX and a simplified version predict Survival in Patients with Large B-Cell Lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study
2025 F. Stella, M. Pennisi, A. Chiappella, B. Casadei, S. Bramanti, S. Ljevar, P. Chiusolo, A.D. Rocco, M.C. Tisi, P. Angelillo, I. Cutini, M. Martino, A. Barone, F. Bonifazi, A. Santoro, F. Sorà, M. Novo, A.M. Barbui, D. Russo, M. Musso, G. Grillo, M. Krampera, J. Olivieri, L. Brunello, F. Cavallo, M. Massaia, L. Arcaini, L. Farina, P. Zinzani, R. Miceli, P. Corradini
Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis
2025 M. Perales, F.T. Awan, A. Boumendil, J. Patel, L. Castagna, E. Angelucci, H. Finel, A. Kulagin, B. Glass, P. Corradini, A.F. Herrera, D. Blaise, M.A. Kharfan-Dabaja, K. Halahleh, S. Ahmed, C. Martínez, S. Giebel, S. Montoto, R.J. Jones, N. Ahmed, R.C. Lynch, M.J. De Lima, M. Shadman, C.S. Sauter, K.W. Ahn, M. Hamadani, A. Bazarbachi, A. Sureda
Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis
2025 A. Dodero, G. Ceparano, B. Casadei, P. Angelillo, S. Bramanti, M.C. Tisi, S. Ljevar, F. Stella, A. Chiappella, B. Botto, I. Cutini, G. Zanirato, P. Chiusolo, A.M. Barbui, M. Farina, A. Di Rocco, G. Grillo, J. Olivieri, M. Krampera, M. Ladetto, A. Guidetti, P.L. Zinzani, C. Carniti, P. Corradini
Rituximab, bendamustine, and cytarabine followed by venetoclax in older patients with high-risk mantle cell lymphoma (FIL_V-RBAC): a multicentre, single-arm, phase 2 study
2025 C. Visco, V. Tabanelli, M.V. Sacchi, A. Evangelista, F.M. Quaglia, S. Fiori, R. Bomben, M.C. Tisi, M. Riva, A. Merli, F. Rotondo, C. Fraenza, M.E. Carazzolo, P. Corradini, L. Farina, C. Castellino, A. Castellino, V.R. Zilioli, C. Muzi, F. Piazza, A. Re, S. Hohaus, F.G. Rossi, G. Musuraca, A. Di Rocco, B. Puccini, R. Sciarra, F. Ballerini, F. Cavallo, R. Bruna, R. Moia, A. Moioli, A. Bernardelli, D. Drandi, A. Arcari, F. Merli, G. Gini, R. Freilone, M. Tani, V. Pavone, M. Ladetto, S.A. Pileri, M. Balzarotti
Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes
2025 A. Barone, C. De Philippis, F. Stella, A. Dodero, B. Sarina, M. Pennisi, A. Santoro, C. Carlo-Stella, A. Guidetti, S. Bramanti, P. Corradini
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
2025 G. Damaj, A. Bazarbachi, P. Berning, A. Cottereau, C.P. Fox, C. Kyriakou, K. Cwynarski, P. Zinzani, O. Tournilhac, W. Jurczak, I.E. Karsten, F. Wang, A. Marcais, A. Tanase, S. Nguyen-Quoc, Y. Serroukh, M. Aljurf, D. Beauvais, G. Wulf, A. Sureda, P. Corradini, O. Hermine, M. Hamadani, F. Onida, A.L. Ruggeri, I. Sanchez-Ortega, I. Yakoub-Agha, P. Dreger, N. Schmitz
A SWOT-consensus for CAR-T in follicular lymphoma: fine tuning of patient journey and selection
2025 M. Marchetti, P. Corradini, L. Arcaini, S. Bramanti, A. Di Rocco, M. Ladetto, S. Luminari, L. Rigacci, P.L. Zinzani
Prognostic role of interim PET in patients with follicular lymphoma: a post-hoc study of FOLL12 trial by FIL
2025 R. Durmo, S. Chauvie, F. Fallanca, F. Bergesio, A. Pinto, I. Del Giudice, M. Coscia, P. Corradini, E. Angelucci, P. Tosi, R. Freilone, F. Ballerini, A. Bari, D. Pastore, P.L.L. Zinzani, S.A.M. Bolis, L. Flenghi, A. Liso, J. Olivieri, L. Marcheselli, M. Merli, A. Versari, L. Guerra, S. Luminari